ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal first quarter, ended September 30, 2018. CSI’s first-quarter revenues were $56.3 million, an increase of $6.6 million, […]
Financial
Novoheart to Generate USD $1.7m From Strategic Partnership to Build Good Manufacturing Practice Facility to Create Clinical-Grade Human Stem Cell Libraries
VANCOUVER, British Columbia, Oct. 31, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that it has entered into a service agreement with Xellera Therapeutics Limited, representing Phase 1 of an intended long-term strategic partnership between the companies. […]
iRhythm Technologies Announces Third Quarter Financial Results
SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ending September 30, 2018. Third Quarter 2018 Highlights Revenue of $38.1M – 52% increase compared to […]
LivaNova Reports Third Quarter 2018 Results
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2018. For the third quarter of 2018, worldwide sales from continuing operations were $272.1 million, an increase of 8.3 percent on a reported basis and an increase of 10.3 percent on […]
Endologix, Inc. to Present at Two Investor Conferences in November
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will present at the following two investor conferences in November: Conference: Stephens NY Investment Conference Location: New York, NY Date: Tuesday, November 6, 2018 Presentation: 7:30 a.m. ET Speakers: Vaseem Mahboob, […]
REVA to Hold Third Quarter 2018 Financial Results Call
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) has scheduled a conference call to review its third quarter 2018 financial results and provide a business update. The call is scheduled for 2:00 p.m. US PST on Monday, November 5, 2018 (which […]
Hemostemix Announces OTCQB Listing and DTC Eligibility
CALGARY, Alberta, Oct. 30, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce the Company has been approved for up-listing its common shares for trading on the OTCQB Venture Market, a US trading platform that is operated by the OTC […]
InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6
TEL AVIV, Israel, Oct. 30, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, November 6, […]
Merit Medical Reports Earnings for Third Quarter of 2018
SOUTH JORDAN, Utah, Oct. 25, 2018 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced revenue of $221.7 million for the quarter ended […]
Cerenis Therapeutics Announces Its Cash Position for Q3 2018 And Highlights the Progress Made over the Period and Key Perspectives for the end of 2018
October 25, 2018 12:00 PM Eastern Daylight Time TOULOUSE, France & LAKELAND, Fla.–(BUSINESS WIRE)–Regulatory News: Cerenis Therapeutics (Paris:CEREN) (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and HDL platform technologies today announced its cash […]
Recent
Instylla’s Embrace® Hydrogel Embolic System Receives FDA Approval for Peripheral Arterial Bleeds
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Brainomix AI Imaging Analysis of Phase 3 CHARM Trial Identifies Promising Treatment Signals in Severe Stroke Patients
Popular
- No commented posts yet